How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

2,253 results for

adhd Methylphenidate

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

41. White Matter by Diffusion MRI Following Methylphenidate Treatment: A Randomized Control Trial in Males with Attention-Deficit/Hyperactivity Disorder. Full Text available with Trip Pro

White Matter by Diffusion MRI Following Methylphenidate Treatment: A Randomized Control Trial in Males with Attention-Deficit/Hyperactivity Disorder. BackgroundMethylphenidate (MPH) is highly effective in treating attention-deficit/hyperactivity disorder (ADHD). However, not much is known about its effect on the development of human brain white matter (WM).PurposeTo determine whether MPH modulates WM microstructure in an age-dependent fashion in a randomized double-blind placebo-controlled (...) size, 5.25) in MPH-treated boys. Similar changes were not present in boys receiving a placebo, nor in adult men.ConclusionFour months of treatment with methylphenidate affects specific tracts in brain white matter in boys with attention-deficit/hyperactivity disorder. These effects seem to be age dependent, because they were not observed in adults treated with methylphenidate.© RSNA, 2019Online supplemental material is available for this article.

2019 Radiology Controlled trial quality: predicted high

42. The effect of methylphenidate on social cognition and oxytocin in children with attention deficit hyperactivity disorder. (Abstract)

The effect of methylphenidate on social cognition and oxytocin in children with attention deficit hyperactivity disorder. The current study aimed to explore the possible effect of stimulants on oxytocin (OT), a neuropeptide which regulates social behavior, as a mediator of the pro-social effect of methylphenidate (MPH) in children with attention deficit hyperactivity disorder (ADHD) compared to healthy controls (HCs). Utilizing a double-blind placebo-controlled design, we compared (...) with an increase in OT levels after the parent-child interaction. We conclude that OT might play a role as a mediator of social deficits in children with ADHD and that the reactivity of the OT system to social interaction in children with ADHD might be impaired. Stimulants may improve ToM and social functions in children with ADHD via its impact on the OT system. PRS: OT and Social Cognition in Children with ADHD: Impact of MPH.

2019 Neuropsychopharmacology

43. Correction: The effect of methylphenidate on social cognition and oxytocin in children with attention deficit hyperactivity disorder. Full Text available with Trip Pro

Correction: The effect of methylphenidate on social cognition and oxytocin in children with attention deficit hyperactivity disorder. An amendment to this paper has been published and can be accessed via a link at the top of the paper.

2019 Neuropsychopharmacology

44. Combination Therapy for Attention Deficit Hyperactivity Disorder: A Review of the Clinical Effectiveness

patients with ADHD. Tags amphetamine, attention deficit disorder with hyperactivity, delayed-action preparations, dexamfetamine, dexedrine, dexmethylphenidate, dextroamphetamine, focalin, learning disorders, methylphenidate, ritalin, learning disorder, AD/HD, ADD, Adderall, Attention deficit, Concerta, Long acting, Slow acting, atomoxetine, controlled delivery, controlled release, delayed release, extended release, immediate release, lisdexamfetamine dimesylate, short acting, sustained release, vyvanse (...) Combination Therapy for Attention Deficit Hyperactivity Disorder: A Review of the Clinical Effectiveness Combination Therapy for Attention-Deficit/Hyperactivity Disorder: A Review of the Clinical Effectiveness | CADTH.ca Find the information you need Combination Therapy for Attention-Deficit/Hyperactivity Disorder: A Review of the Clinical Effectiveness Combination Therapy for Attention-Deficit/Hyperactivity Disorder: A Review of the Clinical Effectiveness Published on: February 23, 2016

2016 Canadian Agency for Drugs and Technologies in Health - Rapid Review

45. High-dose Stimulants for Attention Deficit Hyperactivity Disorder: A Review of the Clinical Effectiveness, Safety and Guidelines

in adolescents with ADHD was identified; high doses of study medication were more effective than placebo at addressing symptoms, but had uncertain effects on quality of life measures. Three non-randomized studies regarding adverse events for adolescents and adults using high doses of methylphenidate were identified; these doses were generally well tolerated by patients. Tags amphetamine, amphetamines, attention deficit disorder with hyperactivity, central nervous system stimulants, dexamfetamine, dexedrine (...) : A Review of the Clinical Effectiveness, Safety, and Guidelines Published on: March 3, 2016 Project Number: RC0754-000 Product Line: Research Type: Drug Report Type: Summary with Critical Appraisal Result type: Report Question What is the effectiveness and safety of high dose stimulants in children and adolescents (six to 18 years) with attention-deficit/hyperactivity disorder (ADHD)? What is the comparative effectiveness and safety of high dose stimulants in adults (> 18 years) with ADHD? What

2016 Canadian Agency for Drugs and Technologies in Health - Rapid Review

46. Empathy and Facial Expression Recognition in Children With and Without Attention-Deficit/Hyperactivity Disorder: Effects of Stimulant Medication on Empathic Skills in Children with Attention-Deficit/Hyperactivity Disorder. (Abstract)

Empathy and Facial Expression Recognition in Children With and Without Attention-Deficit/Hyperactivity Disorder: Effects of Stimulant Medication on Empathic Skills in Children with Attention-Deficit/Hyperactivity Disorder. The aim of this study was to compare children and adolescents with attention-deficit/hyperactivity disorder (ADHD) to healthy children and adolescents in terms of state and trait empathy and emotion expression recognition skills. The goal was also to determine whether (...) there are changes in emotion recognition and empathy measures in children with ADHD after methylphenidate (MPH) treatment.The research sample consisted of outpatient drug-naive children and adolescents between the age of 8 and 14 years (n = 65) with ADHD according to the Diagnostic and Statistical Manual of Mental Disorders, 4th ed. criteria, and healthy children and adolescents of the same age (n = 61). Scores of the oppositional problems (OPs) and conduct problems (CPs) were obtained to evaluate their impact

2017 Journal of Child and Adolescent Psychopharmacology Controlled trial quality: uncertain

47. A multicentre randomized controlled trial on trans-generational attention deficit/hyperactivity disorder (ADHD) in mothers and children (AIMAC): an exploratory analysis of predictors and moderators of treatment outcome. Full Text available with Trip Pro

A multicentre randomized controlled trial on trans-generational attention deficit/hyperactivity disorder (ADHD) in mothers and children (AIMAC): an exploratory analysis of predictors and moderators of treatment outcome. We examined predictors and moderators of treatment outcome in mothers and children diagnosed with ADHD in a large multicentre RCT.In total, 144 mother-child dyads with ADHD were randomly assigned to either a maternal ADHD treatment (group psychotherapy and open methylphenidate (...) in the family at baseline predicted more externalizing symptoms in the child after PCT, independent of maternal treatment. When mothers had a comorbid depression, TG children showed more externalizing symptoms after PCT than CG children of depressive mothers. No differences between the treatment arms were seen in the mothers without comorbid depression.Severely impaired mothers with ADHD and depressive disorder are likely to need additional disorder-specific treatment for their comorbid psychiatric

2019 Zeitschrift fur Kinder- und Jugendpsychiatrie und Psychotherapie Controlled trial quality: uncertain

48. The effect of methylphenidate on decision making in patients with borderline personality disorder and attention-deficit/hyperactivity disorder. (Abstract)

The effect of methylphenidate on decision making in patients with borderline personality disorder and attention-deficit/hyperactivity disorder. Impaired decision making in patients with borderline personality disorder (BPD) has been reported in several studies. Although methylphenidate (MPH) is known to ameliorate impaired decision making in patients with attention-deficit/hyperactivity disorder (ADHD), it has not yet been examined in patients with BPD. We therefore assessed the efficacy (...) of a single dose of MPH on cognitive functions and decision making in patients with BPD. Twenty-two patients diagnosed with BPD participated in the study. The study was a randomized, double-blind placebo-controlled, random block order cross-over trial. Patients participated in two sessions and performed the Test of Variables of Attention, a digit-span test, and the computerized Iowa Gambling Task, after they had been administered either the MPH or a placebo. ADHD symptoms were assessed using the Adult

2018 International clinical psychopharmacology Controlled trial quality: uncertain

49. Aripiprazole/Methylphenidate Combination in Children and Adolescents with Disruptive Mood Dysregulation Disorder and Attention-Deficit/Hyperactivity Disorder: An Open-Label Study. (Abstract)

Aripiprazole/Methylphenidate Combination in Children and Adolescents with Disruptive Mood Dysregulation Disorder and Attention-Deficit/Hyperactivity Disorder: An Open-Label Study. Disruptive mood dysregulation disorder (DMDD) is characterized by nonepisodic irritability and has a high rate of comorbidity with attention-deficit/hyperactivity disorder (ADHD). This is the first study to explore the effects of aripiprazole combined with methylphenidate on clinical symptoms and cognitive functions (...) group consisting of patients with ADHD (the ADHD Group, n = 27) was recruited to investigate the differences in clinical and neuropsychological profiles between the two groups at baseline.The DMDD-ADHD Group showed worse irritability, disruptive behaviors, anxious/depressed symptoms, and social problems relative to the ADHD Group at baseline assessments. The combination treatment significantly improved irritability, externalizing symptoms, depression, anxiety, attention, social problems

2018 Journal of Child and Adolescent Psychopharmacology Controlled trial quality: uncertain

50. Improvements in Irritability with Open-Label Methylphenidate Treatment in Youth with Comorbid Attention Deficit/Hyperactivity Disorder and Disruptive Mood Dysregulation Disorder. Full Text available with Trip Pro

Improvements in Irritability with Open-Label Methylphenidate Treatment in Youth with Comorbid Attention Deficit/Hyperactivity Disorder and Disruptive Mood Dysregulation Disorder. The purpose of this open-label study was to examine the effects of long-acting methylphenidate (MPH) treatment on irritability and related emotional symptoms associated with disruptive mood dysregulation disorder (DMDD) in youth with comorbid attention-deficit/hyperactivity disorder (ADHD).The sample included 22 (...) , and negative affect (NA). Multiple regression was used to examine the impact baseline hyperactivity, age, gender, race, socioeconomic status, or comorbid diagnosis had on treatment outcomes.Significant improvements (medium to large effect sizes) in child-rated irritability as well as parent and child ratings of emotional lability, NA, and anger were found. As anticipated, ADHD symptoms also improved. While a majority of the sample saw improvement in child-rated irritability (71%), symptoms worsened a small

2018 Journal of Child and Adolescent Psychopharmacology

51. Social adjustment and family function after drug switch from IR-methylphenidate to OROS-methylphenidate in patients with attention-deficit/hyperactivity disorder Full Text available with Trip Pro

Social adjustment and family function after drug switch from IR-methylphenidate to OROS-methylphenidate in patients with attention-deficit/hyperactivity disorder This prospective, single-arm, open-label, 8-week, multicenter study investigated the effectiveness of switching from immediate-release methylphenidate (IR-MPH) to osmotic controlled-release methylphenidate (OROS-MPH) in patients with attention-deficit/hyperactivity disorder (ADHD).Overall, 296 patients with ADHD (mean age: 9.5 years (...) to OROS-MPH improved patients' behavioral ADHD symptoms and social adjustment, and mental health of patients' mothers. This was most evident in patients who previously exhibited poor IR-MPH adherence.

2018 Neuropsychiatric disease and treatment

52. Attention deficit hyperactivity disorder in children and young people: lisdexamfetamine dimesylate

hyperactivity disorder (ADHD) in children aged 6 years and over when response to previous methylphenidate treatment is considered clinically inadequate. Lisdexamfetamine dimesylate is a pharmacologically inactive pro-drug that is converted into the central nervous system stimulant, dexamfetamine. Attention deficit hyperactivity disorder: diagnosis and management of ADHD in children, young people and adults (NICE guideline CG72, published in 2008) recommends that drug treatment for children and young people (...) with ADHD should always form part of a comprehensive treatment plan that includes psychological, behavioural and educational advice/interventions. It also recommends Attention deficit hyperactivity disorder in children and young people: lisdexamfetamine dimesylate (ESNM19) © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 2 of 20that when drug treatment of ADHD is considered appropriate, methylphenidate, atomoxetine

2013 National Institute for Health and Clinical Excellence - Advice

53. Attention deficit hyperactivity disorder in children and young people: clonidine

), British national formulary (BNF) or the MHRA or NICE websites for up- to-date information. Clonidine is an alpha 2 -adrenergic agonist that is licensed in the UK for adults to prevent migraine, prevent hot flushing associated with menopause, and treat hypertension. It does not have a UK licence to treat attention deficit hyperactivity disorder (ADHD) in any age group. It is sometimes used off-label (generally as an add-on to a licensed psychostimulant medicine, such as methylphenidate) to treat ADHD (...) in children and young people under 18 years. This review does not include evidence for the use of extended-release clonidine preparation (Kapvay), which is approved in the USA for treating ADHD. NICE has issued a clinical guideline on Attention deficit hyperactivity disorder: diagnosis and management of ADHD in children, young people and adults (NICE clinical guideline 72). This recommends that in children and young people whose ADHD is unresponsive to methylphenidate, atomoxetine and dexamfetamine

2013 National Institute for Health and Clinical Excellence - Advice

54. High Dose Stimulants for Attention Deficit Hyperactivity Disorder

, and evidence-based guidelines. One systematic review, three randomized-controlled trials, and four non-randomized studies were identified regarding high dose stimulants for attention deficit hyperactivity disorder. Additional references of potential interest are provided in the appendix. Health Technology Assessments No literature identified. Systematic Reviews and Meta-analyses 1. Epstein T, Patsopoulos NA, Weiser M. Immediate-release methylphenidate for attention deficit hyperactivity disorder (ADHD (...) Adolesc Psychopharmacol. 2010 Feb;20(1):49-54. PubMed: PM20166796 High Dose Stimulants for ADHD 4 Adults 8. Adler LA, Orman C, Starr HL, Silber S, Palumbo J, Cooper K, et al. Long-term safety of OROS methylphenidate in adults with attention-deficit/hyperactivity disorder: an open- label, dose-titration, 1-year study. J Clin Psychopharmacol. 2011 Feb;31(1):108-14. PubMed: PM21192153 Guidelines and Recommendations No literature identified. PREPARED BY: Canadian Agency for Drugs and Technologies

2015 Canadian Agency for Drugs and Technologies in Health - Rapid Review

55. Co Morbid Attention Deficit and Hyperactivity Disorder(ADHD) and Developmental Co Ordination Disorder (DCD)

Product: No Keywords provided by Pam Dawson, University of KwaZulu: ADHD/ADD DCD Exercises Neurostimulant Drugs Additional relevant MeSH terms: Layout table for MeSH terms Disease Attention Deficit Disorder with Hyperactivity Hyperkinesis Motor Skills Disorders Pathologic Processes Attention Deficit and Disruptive Behavior Disorders Neurodevelopmental Disorders Mental Disorders Dyskinesias Neurologic Manifestations Nervous System Diseases Signs and Symptoms (...) Co Morbid Attention Deficit and Hyperactivity Disorder(ADHD) and Developmental Co Ordination Disorder (DCD) Co Morbid Attention Deficit and Hyperactivity Disorder(ADHD) and Developmental Co Ordination Disorder (DCD) - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies

2018 Clinical Trials

56. Risk of suicide attempts in adolescents and young adults with attention-deficit hyperactivity disorder: a nationwide longitudinal study Full Text available with Trip Pro

Risk of suicide attempts in adolescents and young adults with attention-deficit hyperactivity disorder: a nationwide longitudinal study Attention-deficit hyperactivity disorder (ADHD) increases the risk of suicidal behaviours through psychiatric comorbidities; however, a significant direct association has not been observed between ADHD and suicide attempts. Aims To evaluate the risk of suicide attempt in adolescents and young adults with ADHD.Using a nationwide, population-based insurance (...) ). Subgroup analyses of men, women, adolescents and young adults demonstrated the same trend. Methylphenidate or atomoxetine treatment did not increase the risk of suicide attempt or repeated suicide attempts. Long-term methylphenidate treatment was associated with a significantly decreased risk of repeated suicide attempts in men (hazard ratio = 0.46, 95% CI = 0.22-0.97).ADHD was a risk factor for suicide attempt and a stronger predictor of repeated suicide attempts, independent of comorbidities. Further

2018 EvidenceUpdates

57. Natural Health Product-Drug Interaction Causality Assessment in Pediatric Adverse Event Reports Associated with Attention-Deficit/Hyperactivity Disorder Medication. Full Text available with Trip Pro

Natural Health Product-Drug Interaction Causality Assessment in Pediatric Adverse Event Reports Associated with Attention-Deficit/Hyperactivity Disorder Medication. Background: Some pediatric patients with attention-deficit/hyperactivity disorder (ADHD) use natural health products (NHPs) such as herbal remedies. Although herbal remedies are generally considered to be safe when they are used appropriately, they may contain active components that can interact with medications being used (...) to assess multiple potential interactions. Following data extraction and evaluation of completeness, five AERs involving only one herbal remedy and one ADHD medication were evaluated for causality. An NHP-drug interaction was assessed to be probable in one case and to be possible in another. Both these reports involved a methylphenidate formulation and St. John's wort. Conclusions: Eighteen of the 23 identified AERs involving both an herbal remedy and an ADHD drug also involved other multiple ingredient

2020 Journal of Child and Adolescent Psychopharmacology

58. Diagnosis and Treatment Options for Preschoolers with Attention-Deficit/Hyperactivity Disorder. (Abstract)

Diagnosis and Treatment Options for Preschoolers with Attention-Deficit/Hyperactivity Disorder. Objective: The Diagnostic and Statistical Manual of Mental Disorders, fifth edition (DSM-5), classifies attention-deficit/hyperactivity disorder (ADHD) as a neurodevelopmental disorder, with symptoms becoming apparent as early as the preschool years. Early recognition can lead to interventions such as parent/teacher-administered behavior therapy, the recommended first-line treatment for preschool (...) describes different manifestations of ADHD in preschool versus school-aged children, but does not list separate criteria by age group. Importantly, behaviors indicative of ADHD in older children may be developmentally appropriate in preschool children. Several behavioral rating scales have been validated in children younger than 6 years of age for assessing ADHD. The Preschool ADHD Treatment Study (PATS) has provided the most extensive efficacy and safety data on methylphenidate (MPH) for ADHD

2020 Journal of Child and Adolescent Psychopharmacology

59. The Association with Quantitative Response to Attention-Deficit/Hyperactivity Disorder Medication of the Previously Identified Neurodevelopmental Network Genes. Full Text available with Trip Pro

The Association with Quantitative Response to Attention-Deficit/Hyperactivity Disorder Medication of the Previously Identified Neurodevelopmental Network Genes. Objective: A recent pharmacoimaging study suggested that methylphenidate (MPH) and atomoxetine (ATX) might have common mechanisms for the treatment of attention-deficit/hyperactivity disorder (ADHD). Previous pharmacogenetic studies have by and large only involved genes in neurotransmitter systems, which accounted for very small (...) variances. Therefore, this study aimed to investigate whether the neurodevelopmental genes identified in a prior ADHD etiology Genome-Wide Association Study (GWAS) could predict patients' responses to MPH and ATX, given the aforementioned mechanisms of action. Methods: For our sample of 241 patients with ADHD, we assessed the change in the ADHD rating scale (ADHD-RS) total symptom scores from baseline to the end of the 12th week of treatment with either MPH or ATX. We performed association analyses

2020 Journal of Child and Adolescent Psychopharmacology

60. Patterns of Lisdexamfetamine Dimesylate Use in Children, Adolescents, and Adults with Attention-Deficit/Hyperactivity Disorder in Europe. Full Text available with Trip Pro

Patterns of Lisdexamfetamine Dimesylate Use in Children, Adolescents, and Adults with Attention-Deficit/Hyperactivity Disorder in Europe. Objectives: Lisdexamfetamine dimesylate (LDX) is approved in some European countries for the second-line treatment of attention-deficit/hyperactivity disorder (ADHD) in children and adolescents when response to previous methylphenidate (MPH) treatment is considered clinically inadequate, and as a first-line treatment in adults. Limited evidence exists (...) and clinical characteristics, and LDX prescription data included patient age and gender, a recorded diagnosis of ADHD, the number of prescriptions per participant, previous MPH prescription recorded, average daily dose, treatment persistence, discontinuation, and switching of medications. Results: Overall, information for 59,292 patients (437,272 LDX prescriptions) was analyzed. Most patients were male (58.1%-84.3%) and fewer than 1% were under 6 years of age. Extensive use of LDX in adults was observed

2020 Journal of Child and Adolescent Psychopharmacology

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>